Insider Buying: Nuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Acquires 4,500 Shares of Stock

Nuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Ron Bentsur purchased 4,500 shares of the company’s stock in a transaction on Tuesday, December 24th. The stock was purchased at an average price of $4.65 per share, with a total value of $20,925.00. Following the completion of the transaction, the chief executive officer now owns 3,270,924 shares of the company’s stock, valued at approximately $15,209,796.60. This trade represents a 0.14 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Ron Bentsur also recently made the following trade(s):

• On Friday, November 15th, Ron Bentsur bought 20,000 shares of Nuvectis Pharma stock. The shares were purchased at an average price of $4.92 per share, for a total transaction of $98,400.00.

Nuvectis Pharma Stock Performance

Shares of NVCT stock opened at $5.22 on Friday. The stock has a fifty day simple moving average of $6.21 and a two-hundred day simple moving average of $6.45. Nuvectis Pharma, Inc. has a 52-week low of $4.44 and a 52-week high of $12.10. The firm has a market capitalization of $100.86 million, a PE ratio of -4.50 and a beta of 0.20.

Nuvectis Pharma (NASDAQ:NVCT) last released its earnings results on Tuesday, November 5th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.01. During the same period in the previous year, the firm posted ($0.37) EPS. On average, sell-side analysts forecast that Nuvectis Pharma, Inc. will post -1.01 EPS for the current fiscal year.

Hedge Funds Weigh In On Nuvectis Pharma

Several hedge funds have recently modified their holdings of the stock. GSA Capital Partners LLP grew its stake in Nuvectis Pharma by 3.7% during the third quarter. GSA Capital Partners LLP now owns 50,129 shares of the company’s stock valued at $315,000 after acquiring an additional 1,790 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Nuvectis Pharma during the 2nd quarter valued at about $58,000. Nations Financial Group Inc. IA ADV purchased a new position in shares of Nuvectis Pharma during the third quarter valued at about $63,000. Renaissance Technologies LLC increased its holdings in shares of Nuvectis Pharma by 20.7% in the second quarter. Renaissance Technologies LLC now owns 74,500 shares of the company’s stock worth $472,000 after purchasing an additional 12,800 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Nuvectis Pharma by 49.8% in the third quarter. Geode Capital Management LLC now owns 79,716 shares of the company’s stock worth $501,000 after purchasing an additional 26,489 shares during the last quarter. Hedge funds and other institutional investors own 96.77% of the company’s stock.

About Nuvectis Pharma

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.